About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Etv6tm1Sho
targeted mutation 1, Stuart H Orkin
MGI:2177950
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Etv6tm1Sho/Etv6tm1Sho involves: 129S4/SvJae * C57BL/6 MGI:2177955


Genotype
MGI:2177955
hm1
Allelic
Composition
Etv6tm1Sho/Etv6tm1Sho
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Etv6tm1Sho mutation (0 available); any Etv6 mutation (142 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• homozygous mutant embryos were already under-represented and developmetally retarded at E11.5
• no mutant embryos were retrieved after E13.5

cardiovascular system
N
• at E9.0-9.5, homozygous mutant embryos appeared grossly normal with regularly beating hearts and visible blood in their circulation
• at E9.0-9.5, the dorsal aorta, intersomitic vessels and branching head veins of mutant embryos proper appeared histologically normal
• also, at E9.0-9.5, yolk sac-derived embryonic red blood cells were present in the mutant blood vessels
• as early as E9.5, 65% of homozygous mutant embryos (designated type I mutants) displayed yolk sacs that lacked branching vitelline vessels, and formed a honeycomb-like network of interconnecting sinusoids instead
• at E9.5, approximately 35% of homozygous mutant embryos (designated type II mutants) exhibited normal-appearing yolk sac vitelline vessels
• by E10, both type I and type II mutants lacked normal vitelline vessels
• by E10.5, about two-thirds of all mutant embryos were growth-retarded, highly necrotic, and displayed an enlarged pericardial sac; this most likely reflects the fraction of type I mutants that failed to develop normal yolk sac vasculature at E9.5
• the remaining one-third of embryos, presumably type II mutants, lost the vitelline vessels completely and exhibited the same honeycomb-like vasculature as type I mutants

embryo
N
• at E9.0-9.5, the number of somites and appearance of the cranial prominence were unaffected
• at E9.0-9.5, placento-allantoid fusion appeared normal
• as early as E9.5, 65% of homozygous mutant embryos (designated type I mutants) displayed yolk sacs that lacked branching vitelline vessels, and formed a honeycomb-like network of interconnecting sinusoids instead
• at E9.5, approximately 35% of homozygous mutant embryos (designated type II mutants) exhibited normal-appearing yolk sac vitelline vessels
• by E10, both type I and type II mutants lacked normal vitelline vessels
• at E10, type II embryos were also developmentally less severely retarded than type I embryos correlating with a later onset of the yolk sac blood vessel defect
• by E10.5, all homozygous embryos were grossly abnormal: about two-thirds of all embryos were severely growth-retarded
• at E9.0, mutant yolk sacs developed ample sinusoidal spaces, and blood islands with lumens similar in diameter to wild-type, and containing pooled primitive red cells; however, larger lumens were absent in mutant yolk sacs
• notably, endodermal and endothelial cells lining the sinusoids in mutant yolk sacs appeared normal
• the total number and content of the erythroid, macrophage and mixed colonies derived from precursors present in mutant yolk sacs did not differ from control littermates

growth/size/body
• at E10, type II embryos were also developmentally less severely retarded than type I embryos correlating with a later onset of the yolk sac blood vessel defect
• by E10.5, all homozygous embryos were grossly abnormal: about two-thirds of all embryos were severely growth-retarded





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/30/2024
MGI 6.23
The Jackson Laboratory